Phaeochromocytoma — advances through science, collaboration and spreading the word

The first International Symposium on Phaeochromocytoma in 2005 was followed by considerable progress in the field, largely owing to the many collaborations and networks stimulated by that and subsequent meetings. The rich hereditary background of phaeochromocytomas has since provided for strong interdisciplinary links of genetics with personalized diagnostics, imaging and therapeutic interventions.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Dahia, P. L. M. Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity. Nat. Rev. Cancer 14, 108–119 (2014).

    CAS  Article  Google Scholar 

  2. 2.

    Eisenhofer, G., Klink, B., Richter, S., Lenders, J. W. M. & Robledo, M. Metabologenomics of phaeochromocytoma and paraganglioma: an integrated approach for personalised biochemical and genetic testing. Clin. Biochem. Rev. 38, 69–100 (2017).

    PubMed  PubMed Central  Google Scholar 

  3. 3.

    Taïeb, D., Jha, A., Treglia, G. & Pacak, K. Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups. Endocr. Relat. Cancer 26, R627–R652 (2019).

    Article  Google Scholar 

  4. 4.

    Nölting, S., Grossman, A. & Pacak, K. Metastatic phaeochromocytoma: spinning towards more promising treatment options. Exp. Clin. Endocrinol. Diabetes 127, 117–128 (2019).

    Article  Google Scholar 

  5. 5.

    Pacak, K. et al. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. Nat. Clin. Pract. Endocrinol. Metab. 3, 92–102 (2007).

    Article  Google Scholar 

  6. 6.

    Fishbein, L. et al. Comprehensive molecular characterization of pheochromocytoma and paraganglioma. Cancer Cell 31, 181–193 (2017).

    CAS  Article  Google Scholar 

  7. 7.

    Crona, J., Taïeb, D. & Pacak, K. New perspectives on pheochromocytoma and paraganglioma: toward a molecular classification. Endocr. Rev. 38, 489–515 (2017).

    Article  Google Scholar 

  8. 8.

    Job, S. et al. Telomerase activation and ATRX mutations are independent risk factors for metastatic pheochromocytoma and paraganglioma. Clin. Cancer Res. 25, 760–770 (2019).

    CAS  Article  Google Scholar 

  9. 9.

    Taïeb, D. et al. European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur. J. Nucl. Med. Mol. Imaging 46, 2112–2137 (2019).

    Article  Google Scholar 

  10. 10.

    Lenders, J. W. M. et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 99, 1915–1942 (2014).

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Karel Pacak.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Related links

International Collaboration on Cancer Reporting: www.iccr-cancer.org/datasets

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Pacak, K., Eisenhofer, G. & Tischler, A.S. Phaeochromocytoma — advances through science, collaboration and spreading the word. Nat Rev Endocrinol 16, 621–622 (2020). https://doi.org/10.1038/s41574-020-00413-w

Download citation

Further reading

Search

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing